|
|
(HealthNewsDigest.com) – Surgeons who conducted clinical trials to test Infuse Bone Graft, a Medtronic bone-growth protein widely used in spine surgery, didn’t report serious complications that arose in those trials in their research papers, a new study says.
Over the past decade, 15 of those surgeons have collectively received at least $62 million from the medical-device giant for unrelated work, according to a Wall Street Journal analysis of Medtronic documents and of recent disclosures made on the company’s website.
http://online.wsj.com/article/SB10001424052702303627104576413663395567784.html?mod=djemalertNEWS
###
Subscribe to our FREE Ezine and receive current Health News, be eligible for discounted products/services and coupons related to your Health. We publish 24/7.
www.HealthNewsDigest.com
For advertising/promotion, email: [email protected] Or call toll free: 877- 634-9180